Hiramoto Nobuhiro, Yamazaki Hirohito, Nakamura Yukinori, Uchida Naoyuki, Murata Makoto, Kondo Tadakazu, Yoshioka Satoshi, Eto Tetsuya, Nishikawa Akinori, Kimura Takafumi, Ichinohe Tatsuo, Atsuta Yoshiko, Onishi Yasushi, Suzuki Ritsuro, Mori Takehiko
Department of Hematology, Kobe City Medical Center General Hospital, 2-2-1, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Ann Hematol. 2022 Jan;101(1):165-175. doi: 10.1007/s00277-021-04664-z. Epub 2021 Sep 21.
Thus far, there have been no large cohort studies on total body irradiation (TBI)-containing conditioning regimens without antithymocyte globulin (ATG) in adults with aplastic anemia (AA) undergoing umbilical cord blood (UCB) transplantation (UCBT). We retrospectively analyzed 115 adults with idiopathic AA undergoing UCBT using TBI-containing reduced-intensity conditioning (RIC) regimens without ATG between 2000 and 2018 on behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. We then compared transplantation outcomes between a fludarabine (Flu)- and melphalan (Mel)-based regimen (FM) and a Flu- and cyclophosphamide (Cy)-based regimen (FC). The median patient age at UCBT was 41 years. The median total nucleated cell and total CD34 cell doses in a UCB unit at cryopreservation were 2.5 × 10/kg and 0.7 × 10/kg, respectively. The median follow-up period for survivors was 47 months. The cumulative incidence rate of neutrophil engraftment was 76.5%, and the 4-year overall survival (OS) rate was 64.3%. In multivariate analysis, the covariates that were significantly associated with a higher neutrophil engraftment were total CD34 cell dose in an UCB unit (≥ 0.7 × 10/kg; hazard ratio, 0.57, P = 0.01) and total dose of TBI (4 Gy of TBI; hazard ratio, 0.32, P = 0.01). There was no significant difference in the cumulative incidence of neutrophil engraftment and the 4-year OS between the FM and FC groups. In conclusion, TBI-containing RIC regimens without ATG are suitable for adults with AA undergoing UCBT. There were no significant differences in transplantation outcomes between the FM and FC groups.
迄今为止,对于接受脐带血移植(UCBT)的再生障碍性贫血(AA)成年患者,尚未有关于不含抗胸腺细胞球蛋白(ATG)的含全身照射(TBI)预处理方案的大型队列研究。我们代表日本造血细胞移植学会成人再生障碍性贫血工作组,回顾性分析了2000年至2018年间115例接受不含ATG的含TBI减低强度预处理(RIC)方案的特发性AA成年患者进行UCBT的情况。然后我们比较了基于氟达拉滨(Flu)和马法兰(Mel)的方案(FM)与基于Flu和环磷酰胺(Cy)的方案(FC)之间的移植结局。UCBT时患者的中位年龄为41岁。冻存时一个脐带血单位中的中位总核细胞和总CD34细胞剂量分别为2.5×10/kg和0.7×10/kg。幸存者的中位随访期为47个月。中性粒细胞植入的累积发生率为76.5%,4年总生存(OS)率为64.3%。在多变量分析中,与较高中性粒细胞植入显著相关的协变量是脐带血单位中的总CD34细胞剂量(≥0.7×10/kg;风险比,0.57,P = 0.01)和TBI的总剂量(4 Gy的TBI;风险比,0.32,P = 0.01)。FM组和FC组之间中性粒细胞植入的累积发生率和4年OS无显著差异。总之,不含ATG的含TBI的RIC方案适用于接受UCBT的AA成年患者。FM组和FC组之间的移植结局无显著差异。